Kupando GmbH
Roberto Maj is an experienced professional in the pharmaceutical and biotechnology industries, currently serving as the Head of Operations at Kupando GmbH since May 2022. Previously, Roberto held key positions in drug development and operations at Gain Therapeutics, INOSITEC AG, Amal Therapeutics, Telormedix, and Brane discovery. Additionally, Roberto's earlier career included roles in preclinical development and quality assurance at mondoBIOTECH AG, Newron Pharmaceuticals SpA, and Pharmacia & Upjohn. Roberto holds a Doctorate in Pharmacy with a focus on Neuropharmacology and Neuroscience from Università degli Studi di Milano, where education was completed from 1976 to 1981.
This person is not in any teams
This person is not in any offices
Kupando GmbH
Kupando is a pioneering biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases. The Company uses its small molecule-based drug candidates to build a pipeline in several indications, in-house or via strategic partnerships, as single agent, or in combination with checkpoint inhibitors, other drugs or antigens. Its drug candidate KUP101 is the only TLR 4/7 agonist in development and consists of two small molecules, TLR4 agonist and TLR7 agonist, co-encapsulated. IND-enabling work is on-going for treatment of solid tumors and prophylaxis of infectious diseases. Kupando is a private company, seed financed by its CEO Johanna Holldack and based on technology invented by Dennis Carson’s Laboratory at the University of California San Diego. The Company’s management team brings a unique wealth of experience in business and drug development, gained in the US and Europe. Kupando is headquartered in Schoenefeld, Germany.